# EDGAR Filing Document

**Accession Number:** 0001114448
**File Stem:** 0001114448-26-000006
**Filing Date:** 2026-2
**Character Count:** 2756
**Document Hash:** 531d5433027520b369fc76fc560fc782
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001114448-26-000006.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001114448-26-000006

**CONFORMED SUBMISSION TYPE**: IRANNOTICE

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVARTIS AG
- **CENTRAL INDEX KEY:** 0001114448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** IRANNOTICE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15024
- **FILM NUMBER:** 26595983

**BUSINESS ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056
- **BUSINESS PHONE:** 01141613241111

**MAIL ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056

---

| | |
|:---|:---|
| <br>![](logorm.jpg) | **** <br>**** <br>**** <br>**Novartis AG** <br> P.O. Box <br> CH 4002 Basel<br>|

---

---

| | |
|:---|:---|
| **US Securities and Exchange Commission**<br> **100 F Street, N.E.** <br> **Washington, DC 20549**<br>Basel, February 4, 2026  | **US Securities and Exchange Commission**<br> **100 F Street, N.E.** <br> **Washington, DC 20549**<br>Basel, February 4, 2026  |
| **Re:**<br>| **Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934** |
| <br>**Ladies and Gentlemen:** <br>Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.<br>Respectfully submitted,<br>Novartis AG | <br>**Ladies and Gentlemen:** <br>Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 4, 2026.<br>Respectfully submitted,<br>Novartis AG |

---

---

| | |
|:---|:---|
| /s/ Karen L. Hale <br>| /s/ Harry Kirsch <br>|
| Karen L. Hale<br> Chief Legal & Compliance Officer of Novartis<br>| Harry Kirsch<br> Chief Financial Officer of Novartis |

---